What is known about this subject? Immunotherapy represents a significant development in cancer treatment, potentially offering durable, long-term remission. Immune checkpoint inhibitors such as nivolumab and pembrolizumab have been approved for a variety of cancer types. There is, however, limited evidence on how immune checkpoint inhibitors are being used generally in routine clinical practice. What this study adds? The uptake of immune checkpoint inhibitors has been swift in Scotland.
Tanja Mueller
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Tanja
Contact Tanja, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack